Inclisiran Sodium for injection + Placebo + Placebos
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Feb 6, 2019 → Sep 9, 2021
NCT ID
NCT03851705About Inclisiran Sodium for injection + Placebo + Placebos
Inclisiran Sodium for injection + Placebo + Placebos is a phase 3 stage product being developed by Novartis for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03851705. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03851705 | Phase 3 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia